Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/22701186
Conclusion of this study
These findings show that up to 9 grams/day of a Tv preparation is safe and tolerable in women with breast cancer in the postprimary treatment setting. This Tv preparation may improve immune status in immunocompromised breast cancer patients following standard primary oncologic treatment.
Supplements analyzed in this study
|
Health conditions analyzed in this study
No health conditions information for this study.Functions related to this study
|
||
|
Body systems related to this study
 Immune System |
